Radient Pharmaceuticals Corporation fka RXPC

[dcspka]

Onko-Sure: Immediate goals for the Canadian marketplace

"Onko-Sure for Lung Cancer" (analysis provided Dec 24, 2014)

"Radient is currently evaluating potential distributors in the Canadian market and aims for a full launch in the Canadian market. The Company is also exploring support from the public payer market in Canada, as a majority of Canadians are covered by their national health plan. The Canadian National Health Plan must approve of funding a test, in addition to the regulatory approval for the efficacy of the test, which Radient has already received. This is an immediate market opportunity for Radient."

This is what William Gartner/GCDx has concentrated on starting with with the recent licensing agreement.

What's interesting about this analysis is that it never mentions GCDx/William Gartner, only Radient. Evidently the research firm (AvaRx) considers the two companies joined at the hip.

http://www.avarx.com/AvaRx/SubDomains/bucket2788312814726325960/Listings/bucket2922583600896136656/Public.Listing.display.html